IL-17RB targeting biobetter (Abeome)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameIL-17RB targeting biobetter (Abeome)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibodyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy

Mechanisms of ActionInterleukin-17 receptor B modulators

TargetsInterleukin-17 receptor B

Therapy Area/IndicationsArthritis

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesAbeome Corp

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesAbeome Corp

Active IndicationsN/A

Inactive IndicationsArthritis

Other Information

ATC CodeN/A